The Christ Hospital Health Network Announces Partnership with Worldwide Clinical Trials in a Collaboration for Leading-Edge Breakthroughs in Oncology Cancer Treatments

The Christ Hospital Health Network (TCHHN) takes another unwavering step forward in its commitment to provide innovative treatment for regional cancer patients.

Cincinnati (October 14, 2021) – The Christ Hospital Health Network (TCHHN) takes another unwavering step forward in its commitment to provide innovative treatment for regional cancer patients. Today, TCHHN announced a partnership with Worldwide Clinical Trials, through Worldwide’s Site Alliance Collaboration, which will increase access to oncology clinical trials and bring revolutionary cancer treatments to regional patients—without traveling beyond the tristate area. “We at The Christ Hospital Health Network are very proud and appreciative of our relationship with Worldwide Clinical Trials,” said Alexander N. Starodub, MD, PhD, Medical Director of Oncology Clinical Trials. “They are an outstanding contract research organization that represents some of the most innovative biotechnology companies in the world.” Dr. Starodub, an oncology and hematology physician, specializes in clinical trials, research, and medical oncology. He holds a PhD in biophysics and is board-certified by the American Board of Internal Medicine with an additional subspecialty certification in medical oncology and hematology. He explained that Worldwide’s talent and infrastructure extend across 60 countries and include a full range of therapies, including access to oncology’s most groundbreaking clinical trials and revolutionary cancer treatments. “This is a global company that has the opportunity to engage in a partnership with any hospital system around the world. Their decision to award us with a partner relationship confirms our program as highly credible and affirms our stance as a health network delivering unparalleled quality healthcare to our patients.” According to Worldwide, oncology clinical trials are notoriously plagued by lengthy study activation periods, which can delay the availability of advanced treatments for cancer patients. Through this partnership, Worldwide Clinical Trials and The Christ Hospital will focus on addressing time-limiting hurdles to reduce the activation period to less than three months on average, ensuring patients with critical needs have faster access to advanced clinical trial options. Worldwide’s mission is to foster the development of life-changing medicines by integrating clinical trial methodology, operational acumen, and efficient technology. According to Clare Wallis, Senior Vice President, Oncology, Worldwide Clinical Trials, its team of oncology experts provide partners with specialized expertise, personalized attention, and the global infrastructure needed to fulfill even their most exacting trials and help solve “the biggest challenges in bringing oncology treatments to patients.” This collaboration, which establishes TCHHN as a significant oncology presence in the region, includes the use of technology developed by world-renowned experts and provides access to scientific research to further the task of finding answers to today’s most pressing oncology issues. “The Christ Hospital Health Network’s mission is to improve the health of the community by creating patient value, and part of the way that we are doing that is by continuously evolving the scope and depth of our capabilities and programs in Oncology,” said Debbie Hayes, President and CEO of The Christ Hospital Health Network. “As such, we are proud to partner with Worldwide Clinical Trials and to expand access to these potentially life -saving clinical trials for those in our community afflicted with a number of cancer diagnoses. “Through this partnership, we now offer treatment options and services that previously have only been available from academically focused medical universities,” said Dr. Starodub. “With access to these phenomenal clinical trials locally, our patients do not need to leave Cincinnati to participate in cutting-edge clinical research opportunities.”